Granted Patent
B2
US 12,257,350 · App. 17/685,830 · Granted Mar 25, 2025
Pharmaceutical compositions of pimobendan
A61K9/5031A61K9/1641A61K9/2081A61K9/5015A61K9/5089A61K31/341A61K31/501A61K31/55A61K31/585A61K31/635A61K45/06A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method for the preparation of a composition includes dispersing particulate pimobendan in a molten carrier matrix to form particles coated with the carrier matrix, where the molten carrier matrix includes one or more pharmaceutically acceptable carriers selected from a polyglycolized glyceride, a polyethylene glycol, and combinations thereof, atomizing the dispersion of coated particles, and cooling and collecting the coated particles from the atomized dispersion.
Claims (12)
1. A composition comprising a plurality of granules, each granule consisting of a spherical particle coated with a lipid carrier matrix, wherein each particle consists of pimobendan, and the lipid carrier matrix consists of polyethylene glycol, wherein the lipid carrier matrix that coats each particle ensures a dissolution of pimobendan in a solution irrespective of a pH condition of the solution.
2. The composition of claim 1 , wherein the lipid carrier matrix is configured to ensure a dissolution of pimobendan within the composition that is from 90.7% to 96.2% when exposed to pH conditions of 1.2, 4.5 and 7.5 for a period of 45 minutes, and the dissolution is determined using ultra high pressure liquid chromatography (UHPLC).
3. The composition of claim 1 , wherein the polyethylene glycol has an average molecular weight from 4,000 to 6,000 g/mol.
4. The composition of claim 1 , wherein a median particle size distribution value (D50 value) of the spherical particles is less than 500 μm, or is less than 300 μm, or is less than 250 μm, or is less than 200 μm.
5. The composition of claim 1 , wherein an amount of pimobendan in each granule is from 1% to 80% by weight of the granule.
6. The composition of claim 1 , wherein an amount of pimobendan in each granule is from 5% to 30% by weight of the granule.
7. The composition of claim 1 , wherein an amount of pimobendan in each granule is from 10% to 20% by weight of the granule.
8. The composition of claim 1 , wherein an amount of pimobendan within the composition is 6.3% by weight of the composition.
9. The composition of claim 1 , wherein an amount of pimobendan present in the composition is from 0.01% to 10% by weight of the composition.
10. The composition of claim 1 , wherein an amount of pimobendan present in the composition is from 0.5% to 1.0% by weight of the composition.
11. A tablet comprising the composition of claim 1 , wherein the granules are compressed together with one or more other ingredients.
12. A formulation comprising a paste or gel that includes the composition of claim 1 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2022
From: LACZAY, PÉTER
To: BOEHRINGER INGELHEIM VETMEDICA GMBH
Reel/Frame 059779/0243 →
Priority Claims (1)
HU 1300702
· Dec 4, 2013
· national
Continuity (4)
References Cited (211)
US 4361563A
· Austel et al.
· 1982
[cited by applicant]
US 4569837A
· Suzuki et al.
· 1986
[cited by applicant]
US 4585790A
· Padfield et al.
· 1986
[cited by applicant]
US 4704284A
· Beatty et al.
· 1987
[cited by applicant]
US 4732915A
· Ayer et al.
· 1988
[cited by applicant]
US 4851226A
· Julian et al.
· 1989
[cited by applicant]
US 4865851A
· James et al.
· 1989
[cited by applicant]
US 4933182A
· Higashi et al.
· 1990
[cited by applicant]
US 4973469A
· Mulligan et al.
· 1990
[cited by applicant]
US 5024998A
· Bodor
· 1991
[cited by applicant]
US 5188836A
· Muhammad et al.
· 1993
[cited by applicant]
US 5364646A
· Gruber et al.
· 1994
[cited by applicant]
US 5472954A
· Loftsson
· 1995
[cited by applicant]
US 5571533A
· Santus et al.
· 1996
[cited by applicant]
US 6407079B1
· Muller et al.
· 2002
[cited by applicant]
US 8183230B2
· Adami et al.
· 2012
[cited by applicant]
US 8409612B1
· Criere et al.
· 2013
[cited by applicant]
US 8846679B2
· Folger et al.
· 2014
[cited by applicant]
US 8846680B2
· Folger et al.
· 2014
[cited by applicant]
US 8859554B2
· Folger et al.
· 2014
[cited by applicant]
US 9107952B2
· Folger et al.
· 2015
[cited by applicant]
US 9616134B2
· Folger et al.
· 2017
[cited by applicant]
US 20030059471A1
· Compton et al.
· 2003
[cited by applicant]
US 20030190343A1
· Thombre et al.
· 2003
[cited by applicant]
US 20040037869A1
· Cleverly et al.
· 2004
[cited by applicant]
US 20040081691A1
· Debregeas et al.
· 2004
[cited by applicant]
US 20040152664A1
· Chang et al.
· 2004
[cited by applicant]
US 20040157887A1
· Whittle et al.
· 2004
[cited by applicant]
US 20040214797A1
· Lyons et al.
· 2004
[cited by applicant]
US 20050095293A1
· Brauns et al.
· 2005
[cited by applicant]
US 20090220611A1
· Dargelas et al.
· 2009
[cited by applicant]
US 20100166857A1
· Yan et al.
· 2010
[cited by applicant]
US 20100183718A1
· Ovaert et al.
· 2010
[cited by applicant]
US 20110189283A1
· Derrieu et al.
· 2011
[cited by applicant]
US 20120308662A1
· Konishi et al.
· 2012
[cited by applicant]
US 20130115301A1
· Bele et al.
· 2013
[cited by applicant]
US 20140363510A1
· Folger et al.
· 2014
[cited by applicant]
AU 2012101682A4
· 2013
[cited by applicant]
CA 1102240A
· 1981
[cited by applicant]
CA 1222697A1
· 1987
[cited by applicant]
CA 2034569A1
· 1991
[cited by applicant]
CA 1336498C
· 1995
[cited by applicant]
CN 1258220A
· 2000
[cited by applicant]
CN 101090735A
· 2007
[cited by applicant]
CN 101316595A
· 2008
[cited by applicant]
CN 101534864A
· 2009
[cited by applicant]
CN 103655502A
· 2014
[cited by applicant]
CN 112618505A
· 2021
[cited by applicant]
DE 3728244A1
· 1989
[cited by applicant]
DE 4001623A1
· 1991
[cited by applicant]
EP 0008391B1
· 1980
[cited by applicant]
EP 0241179A1
· 1987
[cited by applicant]
EP 0306846A2
· 1989
[cited by applicant]
EP 0330052A2
· 1989
[cited by applicant]
EP 0335545A2
· 1989
[cited by applicant]
EP 439030A2
· 1991
[cited by applicant]
EP 1123703A1
· 2001
[cited by applicant]
EP 1247456A2
· 2002
[cited by applicant]
EP 1260215A1
· 2002
[cited by applicant]
EP 1579862A1
· 2005
[cited by applicant]
EP 1903039A1
· 2008
[cited by applicant]
EP 1920785A1
· 2008
[cited by applicant]
EP 2338493A1
· 2011
[cited by applicant]
EP 3034071A1
· 2016
[cited by applicant]
FR 2350105A1
· 1977
[cited by applicant]
GB 1045031A
· 1966
[cited by applicant]
GB 2228004A
· 1990
[cited by applicant]
JP 61500788A
· 1986
[cited by applicant]
JP H029825A
· 1990
[cited by applicant]
JP H03157314A
· 1991
[cited by applicant]
JP H0570612A
· 1993
[cited by applicant]
JP H11228302A
· 1999
[cited by applicant]
JP 2001276597A
· 2001
[cited by applicant]
JP 2002523475A
· 2002
[cited by applicant]
JP 2005521691A
· 2005
[cited by applicant]
JP 2005526738A
· 2005
[cited by applicant]
JP 2005281283A
· 2005
[cited by applicant]
JP 2006507285A
· 2006
[cited by applicant]
JP 2006523687A
· 2006
[cited by applicant]
JP 2007191419A
· 2007
[cited by applicant]
JP 2007536228A
· 2007
[cited by applicant]
JP 2008504308A
· 2008
[cited by applicant]
JP 2008534681A
· 2008
[cited by applicant]
JP 2009114148A
· 2009
[cited by applicant]
JP 2009531451A
· 2009
[cited by applicant]
JP 2009535378A
· 2009
[cited by applicant]
JP 2010508372A
· 2010
[cited by applicant]
JP 2011503044A
· 2011
[cited by applicant]
JP 2011516441A
· 2011
[cited by applicant]
JP 2011157390A
· 2011
[cited by applicant]
JP 2013006798A
· 2013
[cited by applicant]
JP 2013503113A
· 2013
[cited by applicant]
KR 20090084925A
· 2009
[cited by applicant]
WO 1985002767A1
· 1985
[cited by applicant]
WO 1995031963A1
· 1995
[cited by applicant]
WO 1998055148A1
· 1998
[cited by applicant]
WO 2000012137A1
· 1999
[cited by applicant]
WO 2000012138A2
· 2000
[cited by applicant]
WO 2000069414A2
· 2000
[cited by applicant]
WO 2001035925A1
· 2001
[cited by applicant]
WO 2002045693A1
· 2002
[cited by applicant]
WO 2003072141A1
· 2003
[cited by applicant]
WO 2003074032A1
· 2003
[cited by applicant]
WO 2003075895A1
· 2003
[cited by applicant]
WO 2004016252A1
· 2004
[cited by applicant]
WO 2004037201A2
· 2004
[cited by applicant]
WO 2004060353A1
· 2004
[cited by applicant]
WO 2004089418A1
· 2004
[cited by applicant]
WO 2005117911A2
· 2005
[cited by applicant]
WO 2006000229A2
· 2006
[cited by applicant]
WO 2006022562A1
· 2006
[cited by applicant]
WO 2007036671A2
· 2007
[cited by applicant]
WO 2007038796A1
· 2007
[cited by applicant]
WO 2007092026A1
· 2007
[cited by applicant]
WO 2007112274A2
· 2007
[cited by applicant]
WO 2007128749A1
· 2007
[cited by applicant]
WO 2008055871A1
· 2008
[cited by applicant]
WO 2009060226A1
· 2008
[cited by applicant]
WO 2009121585A1
· 2009
[cited by applicant]
WO 2010010257A2
· 2010
[cited by applicant]
WO 2010055119A2
· 2010
[cited by applicant]
WO 2011009818A1
· 2011
[cited by applicant]
WO 2011042463A2
· 2011
[cited by applicant]
WO 2011076738A1
· 2011
[cited by applicant]
WO 2011131259A1
· 2011
[cited by applicant]
WO 2013024023A1
· 2013
[cited by applicant]
WO 2013135852A1
· 2013
[cited by applicant]
WO 2013164473A1
· 2013
[cited by applicant]
WO 2013170317A1
· 2013
[cited by applicant]
WO 2014136035A1
· 2014
[cited by applicant]
WO 2017103054A1
· 2017
[cited by applicant]
WO 2021081366A1
· 2021
[cited by applicant]
“Pharmaceutical Necessities”. Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, Pennsylvania, Chapter 66, 1990, pp. 1288-1300.
[cited by applicant]
“Pimobendan”. The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition, Merck Research Laboratories Division of Merck & Co., Inc., Whitehouse Station, NJ, Index 7515, 2001, p. 1332.
[cited by applicant]
“Vetmedin®—1,25 mg appetizing tablets for dogs Veterinary use”. Summary of Product Characteristics, SCS Boehringer Ingelheim Comm. V, Mar. 25, 2009, pp. 1-4.
[cited by applicant]
Ahmed et al., “Pharmaceutical challenges in veterinary product development”. Advanced Drug Delivery Reviews, vol. 54, 2002, pp. 871-882.
[cited by applicant]
Beaufrere et al., “Therapeutic Review: Pimobendan.” Journal of Exotic Pet Medicine, vol. 18, No. 4, Oct. 2009, pp. 311-313.
[cited by applicant]
Boehringer Ingelheim Vetmedica GmbH, 1st International Canine Valvular Disease Symposium, Paris, Oct. 30-31, 2004, pp. 1-45.
[cited by applicant]
Boehringer Ingelheim Vetmedica, Inc. “Freedom of Information Summary: Original New Animal Drug Application”. NADA 141-273, Vetmedin, Pimobendan Chewable Tablets, Apr. 30, 2007, pp. 1-46.
[cited by applicant]
Bourezg et al., “Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods.” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 413, 2012, pp. 191-199.
[cited by applicant]
Burlage et al., “Other Pharmaceutical Adjuncts”., Physical and Technical Pharmacy, The Blakiston Division: The McGraw-Hill Book Company, Inc., New York, 1963, pp. 653-662.
[cited by applicant]
Dictionary of Veterinary Drugs and Animal Health Products Marketed in France, 12th Edition, 2003, 3 pages.
[cited by applicant]
El-Badry et al., “Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary Systems.” Scientia Pharmaceutica, vol. 79, 2011, pp. 375-386.
[cited by applicant]
Fasinu et al., “Diverse approaches for the enhancement of oral drug bioavailability.” Biopharmaceutics & Drug Disposition, vol. 32, 2011, pp. 185-209.
[cited by applicant]
Fitton et al., “Pimobendan. A Review of its Pharmacology and Therapeutic Potential in Congestive Heart Failure”. Drugs and Aging, vol. 4, No. 5, 1994, pp. 417-441.
[cited by applicant]
Hemati et al., “Fluidized bed coating and granulation: influence of process-related variables and physicochemical properties on the growth kinetics”. Powder Technology, vol. 13, 2002, pp. 18-34.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2014/076073 mailed Feb. 19, 2015.
[cited by applicant]
Kitzen et al., “Pimobendan”. Cardiovascular Drug Reviews, vol. 6, No. 4, 1988, pp. 265-291.
[cited by applicant]
Lachman et al., “The Theory and Practice of Industrial Pharmacy”., 3rd Edition, Lea & Febiger, Philadelphia, 1986, pp. 58-60.
[cited by applicant]
Lai et al., “Real Time and Noninvasive Monitoring of Dry Powder Blend Homogeneity”. AIChE Journal, vol. 47, No. 11, Nov. 2001, pp. 2618-2622.
[cited by applicant]
Lantz et al., “Stability of nizatidine in extemporaneous oral liquid preparations”. American Journal of Hospital Pharmacy, vol. 47, No. 12, Dec. 1990, pp. 2716-2719.
[cited by applicant]
Lewis et al., “Near-Infrared Chemical Imaging for Product and Process Understanding”. in Process Analytical Technology, Second Edition, John Wiley & Sons, Ltd., United Kingdom, 2010, pp. 272-276.
[cited by applicant]
Lezcano et al., “Complexation of Several Benzimidazole-Type Fungicides with Alpha and Beta-Cyclodextrins”. Journal of Agricultural and Food Chemistry, vol. 50, 2002, pp. 108-112.
[cited by applicant]
Lindenberg et al., “Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.” European Journal of Pharmaceut…
[cited by applicant]
Loftsson et al., “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization”. Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996, pp. 1017-1025.
[cited by applicant]
Lyon et al., “Near-Infrared Spectral Imaging for Quality Assurance of Pharmaceutical Products: Analysis of Tablets to Assess Powder Blend Homogeneity”. AAPS PharmSciTech, vol. 3, No. 3, Art. 17, Sep. 2002, pp. 1-15.
[cited by applicant]
Menard et al., “Physico-Chemical Aspects of the Complexation of Some Drugs with Cyclodextrins”. Drug Development and Industrial Pharmacy, vol. 16, No. 1, 1990, pp. 91-113.
[cited by applicant]
Nainar et al., “Biopharmaceutical Classification System in In-vitro/In-vivo Correlation: Concept and Development Strategies in Drug Delivery.” Tropical Journal of Pharmaceutical Research, vol. 11, No. 2, Apr. 2012, pp. …
[cited by applicant]
Petit et al., “VETMEDIN® 1.25 mg, VETMEDIN® 5 mg, Chewable tablets, Inodilator (pimobendan) tablet for dogs”. Dictionary of Veterinary Drugs and Animal Health Products Marketed in France, 16th Edition, Les Editions du P…
[cited by applicant]
Piel et al., “Development of a parenteral and of an oral formulation of albendazole with cyclodextrins”. S.T.P. Pharma Sciences, vol. 9, No. 3, 1999, pp. 257-260.
[cited by applicant]
Redenti et al., “Drug/Cyclodextrin/Hydroxy Acid Multicomponent Systems. Properties and Pharmaceutical Applications”. Journal of Pharmaceutical Sciences, vol. 89, 2000, pp. 1-8.
[cited by applicant]
Rudnic et al., “Oral Solid Dosage Forms”. Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins, Baltimore, Maryland, Chapter 45, 2000, pp. 858-870.
[cited by applicant]
Stuber et al., “The Pharmaceutical and Biological Availability of Commercial Preparations of Furosemide”. Arzneimittel-Forschung, vol. 32, No. 6, 1982, pp. 693-697.
[cited by applicant]
Thiel et al., “Content uniformity of microdose tablets (dosage 1 μg-10 mg) produced by fluid bed granulation of interactive mixtures”. Journal of Pharmacy and Pharmacology, vol. 38, 1986, pp. 335-343.
[cited by applicant]
Upadhyay et al., “Formulation of Fast-Release Gastroretentive Solid Dispersion of Glibenclamide with Gelucire 50/13.” Tropical Journal of Pharmaceutical Research, vol. 11, No. 3, Jun. 2012, pp. 361-369.
[cited by applicant]
Vasconcelos et al., “Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.” Drug Discovery Today, vol. 12, Nos. 23/24, Dec. 2007, pp. 1068-1075.
[cited by applicant]
Vromans et al., “Densification properties and compactibility of mixtures of pharmaceutical excipients with and without magnesium stearate.” International Journal of Pharmaceutics, vol. 46, 1988, pp. 183-192.
[cited by applicant]
Wikipedia, the Free Encyclopedia, “Pimobendan”. [Accessed at: http://en.wikipedia.org/wiki/Pimobenan on Mar. 10, 2014].
[cited by applicant]
Liu et al., “Pharmacology Preparation Technology.” Chemical Industry Press, 2006, pp. 113-114.
[cited by applicant]
Sun et al., “Pimobendan.” Chemical Industry Press, 2002, pp. 29-30.
[cited by applicant]
Teofilo Vasconcelos et al: “solid dispersions a strategy to improve oral bioavailability of poor water soluble drug” , Drug Discovery Today, vol. 12, Jan. 1, 2012 (Jan. 1, 2012), pp. 1068-1075, XP055376574, DOI: 10.1016…
[cited by applicant]
Rekis, T. et al., Cryst. Growth Des. 2018, 18(1): 264-273.
[cited by applicant]
English Abstract CN112618505A.
[cited by applicant]
English Abstract CN103655502A.
[cited by applicant]
Hagemeijer, Frans, Hetty J. Brand, and Willy Roth. “Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and re…
[cited by applicant]
Health and human Services, Guidance for Industry, May 1999, Food and Drug Administration, pp. 1-56.
[cited by applicant]
Rowe RC. et al., Handbook of Pharmaceutical Excipients, Pharmaceutical Press, 6th Edition, USA, 2009, pp. 61-62, 41-442, 596-597, 672-673.
[cited by applicant]
Pharmacy edited by Ning Lin, First Edition, Jan. 2008, p. 283, Hubei Science and Technology Press, Wuhan, Hubei, China.
[cited by applicant]
Food Biochemistry edited by Li Peiqing, First Edition, Jul. 2006, p. 258, Light Industry Press, Beijing, China.
[cited by applicant]
Food Aditives edited by YChi Yujie, First Edition, Apr. 2013, pp. 34-35, China Light Industry, Beijing, China.
[cited by applicant]
Fahelelbom et al., Analysis of preservatives in pharmaceutical products, Pharmaceuticals Reviews Year: 2007 vol. 5 Issue 1. (Year: 2007).
[cited by applicant]
Castro et al., “Interactions Between Additives: Its Effect on Sorbate Stability and Z. bailii Minimum Inhibitory Concentration in Model Aqueous Systems Resembling Salad Dressings,” Food Sci Tech Int 2002;8(1):33-39. (Ye…
[cited by applicant]
Casado et al., “Stability of sorbic and ascorbic acids in packed green table olives during long-term storage as affected by different packing conditions, and its influence on quality parameters,” Food Chemistry, vol. 12…
[cited by applicant]
Liewen et al., “Growth and Inhibition of Microorganisms in the Presence of Sorbic Acid: A Review,”Journal of Food Protection, vol. 48, No. 4, pp. 364-375 (1985). (Year: 1985).
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2005/002133 mailed May 31, 2005.
[cited by applicant]
Abstract in English for JPH03157314A, 1991.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2014076073 mailed on Feb. 9, 2015.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2014065204 mailed on Aug. 14, 2014.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2014065203 mailed on Aug. 14, 2014.
[cited by applicant]
International Search Report and Written Opinion for PCT/EP2007061879 mailed on Mar. 18, 2008.
[cited by applicant]
Lewis, Alan B., “Clinical Profile and Outcome of Restrictive Cardiomyopathy in Children”. American Heart Journal, vol. 123, No. 6, 1992, pp. 1589-1593.
[cited by applicant]